Fig. 2From: Pertuzumab in combination with trastuzumab and chemotherapy for Chinese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subpopulation analysis of the JACOB trialKaplan–Meier plots of overall survival (a) and progression-free survival (b) in the Chinese intention-to-treat subpopulation. Hazard ratio (HR) values with 95% confidence intervals (CIs) are unstratified. Progression-free survival was assessed by the investigator. Patients in both treatment groups received trastuzumab, cisplatin, and a fluoropyrimidine (capecitabine or 5-fluorouracil)Back to article page